FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable or Metastatic Cholangiocarcinoma By Ogkologos - May 20, 2026 50 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Pembrolizumab Combinations Show Promise in mCRPC November 21, 2020 Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients... February 24, 2026 “Your Stories” Podcast: Amplifying Patient Voices September 8, 2020 如何捐赠头发来帮助癌症患者 April 13, 2022 Load more HOT NEWS ESMO AI & Digital Oncology Congress 2025 Closed in Berlin under... Dad Sings “Ave Maria” For His Daughter At Disney World 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Lung... Coping with COVID: New Stimulus Funds and Unemployment Benefit Update
